Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Werfen
| Company | Werfen |
|---|---|
| Instrument name | ACL TOP 770 LAS |
| Contact | Annie Lopatin |
| City State | Bedford, MA |
| Phone | 800-955-9525 |
| Website | |
| First year sold | 2024 |
| List price/Model type | —/floor standing |
| Dimensions (H × W × D)/Weight/Instrument footprint | 64 × 76 × 31 in./400 lbs./16.36 sq. ft. |
| No. of units in clinical use in U.S./Outside U.S. | — |
| Composition of installs: Hospital lab/Reference lab/Other | — |
| Targeted daily, monthly, annual test volume | daily: 200–400; monthly: 6, 000–12, 000; annual: 72, 000–144, 000 |
| Operational type | random access |
| Country where analyzer designed/Manufactured | U.S./U.S. |
| Company manufactures instrument | yes |
| FDA-approved clotting-based tests | PT, APTT, fibrinogen, thrombin time, factor assays, lupus anticoagulant (dRVVT and silica clotting time), protein S, protein C |
| FDA-approved chromogenic tests | anti-Xa, apixaban, rivaroxaban, protein C, antithrombin, plasminogen, plasmin inhibitor, chromogenic factor IX |
| FDA-approved immunologic tests | high specificity D-dimer, standard D-dimer, heparin-induced thrombocytopenia, von Willebrand factor antigen, von Willebrand factor activity, free protein S, factor XIII antigen, homocysteine |
| Other FDA-approved tests | — |
| User-defined tests in clinical use | chromogenic factor VIII |
| Tests in development or awaiting FDA 510(k) clearance | von Willebrand factor ristocetin cofactor, dabigatran, chromogenic factor VIII |
| Methodologies supported | clot detection, optical; chromogenic; immunologic (immunoturbidimetric) |
| Number of different measured assays onboard simultaneously | 36 |
| Number of different assays programmed and calib. at one time | 500 |
| No. of user-definable (open) channels/No. active simultaneously | 250/250 |
| Factor assays require manual manipulation or dilutions | — |
| Test throughput per hour/Assay run time | 220 (1 test in throughput)/dependent on laboratory automation system track manufacturer |
| Design of sample-handling system | samples loaded into rack; integrated sample barcode reader eliminates any post-draw sample misidentification |
| Operates on whole blood or spun plasma | spun plasma |
| Reagent type | self-contained multiuse vials; open reagent system (liquid, lyophilized [reconstituted manually]) |
| Reagent barcode-reading capability | yes, for all tests |
| No. of reagent containers held onboard/Reagents ready to use | 60/variable (reagent specific) |
| Reagent lot tracking/Reagent inventory/Reagents refrigerated onboard | yes/yes/yes (15°C) |
| Reagents, consumables loaded without interrupting testing | yes (reagents and consumables) |
| Instrument uses proprietary or third-party reagents | user’s option (same capabilities when third-party reagents used) |
| Maximum time same lot number of reagents can be used | — |
| Walkaway capability/Walkaway duration | yes/90 specimens or 800 tests |
| Min.–max. specimen volume that can be aspirated at one time | 2–250 µL |
| Min. sample volume required for PT/PTT/Factor VIII activity | 50 µL/50 µL/50 µL |
| Types of disposables used | cuvettes, clean A/B, rinse |
| Primary tube sampling supported/Pierces caps on primary tubes | yes/yes |
| Accommodates most standard tube sizes/Nonstandard sizes | yes/yes (16 × 100 mm) |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Code 39, Code 128)/yes |
| Auto tracks product volume/Measures number of tests remaining | yes/yes |
| Short sample detection | yes |
| Clot detection as preanalytical variable in plasma sample | yes |
| Auto detects adequate reagents for aspiration or analysis | yes (aspiration and analysis) |
| Detection or quantitation for hemolysis, turbidity, icterus, lipemia | detection and quantitation for hemolysis, turbidity, icterus, lipemia |
| Dilutes patient samples onboard | yes |
| Automatic rerun capability/Auto reflex testing capability | yes/yes |
| Lag time during which hypercoagulable sample not detected | no |
| User can adjust reagent volumes/Sample volumes | yes/yes |
| User can adjust No. of reagents/Sources of reagents | yes/yes |
| User can adjust incubation times/Reading times | yes/yes |
| Autocalibration/Calibrants stored onboard | yes/yes |
| Multipoint calibration supported/Recommended frequency | yes/per lab’s quality management system rules |
| • PT alone | <3 minutes/360 specimens |
| • PT, PTT | <6 minutes/165 specimens |
| • Fibrinogen | <3 minutes/108 specimens |
| • Factor VIII activity assay | 8 minutes/100 specimens |
| • D-dimer | 5 minutes/100 specimens |
| Time delay from ordering stat to aspiration of sample | none |
| How labs get LOINC codes for results | website, package insert, email query |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Information that can be barcode-scanned on instrument | specimen identifier, reagent lot No., assigned values, International Sensitivity Index |
| Compatible with laboratory automation systems | yes (Werfen, Beckman, Siemens, Abbott, Thermo Fisher, others) |
| Data-management capability/LIS or EHR systems interfaced | onboard, optional add-on (HemoHub Intelligent Data Manager)/Oracle Health, CompuLab, CPSI, HBOC, HMS, McKesson, Meditech, others |
| Interface supplied by instrument vendor | contract dependent |
| Results transferred to LIS as soon as test time complete | yes |
| Bidirectional interface capability | yes (broadcast download and host query) |
| Remote servicing provided/UPS backup power supply | yes/yes |
| Instrument connections to transfer information | data-management system, which in turn connects to LIS; directly to LIS; directly to lab automation system; commercial middleware (Beckman Coulter) |
| Interface standards supported | ASTM 1394-91 |
| Information transferred to data-management software | device unique identifier, operator ID, patient ID, specimen ID, result, QC identifier, reagent traceability, calibrators and control traceability |
| Avg. time for basic user training | 14 days (10 days at customer site, 4 days at vendor office) |
| Approximate scheduled maintenance time | daily: 5 minutes; weekly: 10 minutes |
| Maintenance records kept onboard | yes |
| Warranty with purchase/Annual service contract cost (24/7) | yes/— (cost dependent on contract) |
| Distinguishing features (supplied by company) | FDA 510(k) approved; improves patient care, lab efficiencies, and costs; liquid format for PT/APTT; supports lab’s policy on sample acceptance with quantitative HIL, sample fill detection, aspiration errors (clots); offers performance verification studies, supporting accreditation requirements |